Overactive Bladder Treatment Market Share, Size and Growth Analysis By 2029

The global market for treating overactive bladder (OAB) is projected to expand from approximately US$ 4,295.93 million in 2021 to around US$ 5,333.92 million by 2028, reflecting a compound annual growth rate (CAGR) of 3.1% from 2022 to 2028.

Overactive bladder is characterized by a frequent and sudden urge to urinate, which can be challenging to manage. Various factors can contribute to OAB, including abdominal injuries, infections, nerve damage, and certain medications. This condition is particularly prevalent among individuals aged 65 and older, with women often experiencing symptoms after the age of 45. Treatment options typically involve behavioral modifications, medications, and nerve stimulation therapies. According to data from the National Association for Incontinence, approximately 200 million people globally were affected by urinary incontinence in 2018. The two most common forms of urinary incontinence in women are stress incontinence and urge incontinence, the latter being synonymous with overactive bladder.

Furthermore, a study by researchers affiliated with the American College of Physicians and the Infectious Diseases Society of America in 2020 revealed that urinary tract infections (UTIs) account for around 6 million doctor visits annually in the United States. In Canada, there are about 500,000 consultations each year related to UTIs. UTIs rank as the eighth and fifth most common reasons for visits to ambulatory clinics and emergency departments, respectively, in Canada. The rising incidence of urinary incontinence, coupled with the increasing occurrence of urinary tract infections, is significantly propelling the growth of the overactive bladder treatment market.

The market for overactive bladder treatment is categorized based on pharmacotherapy, disease type, and geographical regions. Geographically, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report on the overactive bladder treatment market provides comprehensive insights and detailed analyses, focusing on various parameters such as market trends, dynamics, and competitive assessments of leading global players.

In terms of pharmacotherapy, the overactive bladder treatment market is segmented into several categories, including mirabegron, Botox, neurostimulation, anticholinergics, and intravesical instillation. The mirabegron segment dominated the market in 2021 and is expected to exhibit the highest CAGR during the forecast period. Mirabegron is utilized either alone or in combination with solifenacin to manage overactive bladder in adults. Additionally, it is prescribed for treating neurogenic detrusor overactivity in children aged three years and older. As a beta-3 adrenergic agonist, mirabegron works by relaxing the bladder muscles, thereby reducing the frequency and urgency of urination. It is available in both extended-release tablets and oral suspension forms. Notably, in October 2022, Zydus Pharmaceuticals Inc. received approval from the US FDA to market Mirabegron Extended-Release Tablets USP in dosages of 25 mg and 50 mg.

The COVID-19 pandemic has created some favorable conditions for companies operating within the overactive bladder treatment sector. The United States was significantly impacted by the pandemic, particularly among the elderly population, leading to various health complications and a high mortality rate. As of May 16, 2022, the US reported over 84 million COVID-19 cases and approximately 1,026,670 deaths. Consequently, there is a heightened need for effective overactive bladder treatments to mitigate chronic health issues arising from infections.

Post-COVID-19, there has been a notable rise in OAB cases. A study conducted by the American Urological Association indicated that individuals who contracted COVID-19 faced an increased likelihood of developing new or exacerbated overactive bladder symptoms. Approximately one-third of COVID-19 patients reported a significant worsening of symptoms two months post-infection, as assessed by the International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB). Among these patients, about one in five indicated that their OAB symptoms were newly developed. This surge in OAB cases linked to COVID-19 has positively influenced the demand for overactive bladder treatments during the pandemic period.

Key sources utilized in the preparation of the report on the overactive bladder treatment market include the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Office on Women's Health, a division of the US Department of Health and Human Services, among others.